Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that its wholly owned subsidiary has entered into an exclusive licensing agreement with
Under the terms of the agreement,
Tavilermide is a small cyclic peptidomimetic of NGF, a naturally occurring protein in the eye responsible for the maintenance of corneal nerves and epithelium. Tavilermide is differentiated from other investigational therapies in dry eye disease because it induces the production of mucin, a naturally occurring component of the tear film, and works upstream prior to inflammation.
"Mimetogen is excited to work together with
In a previously announced Phase 2 trial (Study Designation MIM-725) tavilermide demonstrated significant improvements in both signs and symptoms with 1% tavilermide versus placebo, together with strong safety, comfort and tolerability profiles. Tavilermide is currently being evaluated in two multi-center Phase 3 clinical studies in
"Dry eye disease continues to be an area where novel therapies are needed to improve the treatment of the disease, including the underlying cause of dry eye, for patients," said
Dry Eye Disease
Dry eye disease can be caused by advanced age, contact lens wear, certain medications, eye diseases, other medical conditions or environmental factors. One type of dry eye is caused by decreased tear production due to inflammation. Without enough tears, the film protecting the eye can break down, creating dry spots on the cornea. Chronic dry eye is estimated to affect 25 million patients in the U.S.
With commercial operations in approximately 100 countries,
For more information, visit
Allergan Forward-Looking Statements
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect
 Market Scope®, 2011 Report on the